<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25004">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834014</url>
  </required_header>
  <id_info>
    <org_study_id>ATOM Exploratory study</org_study_id>
    <secondary_id>UMIN000010429</secondary_id>
    <nct_id>NCT01834014</nct_id>
  </id_info>
  <brief_title>Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases</brief_title>
  <acronym>ATOM ES</acronym>
  <official_title>An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EPS Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EPS Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare of Japan</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The correlation between the values of angiogenesis-related growth factors in plasma and
      efficacy, and biomarkers relevant as prognostic factors or predictive factors for
      sensitivity or resistance to treatment will be examined exploratively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The correlation between the values of angiogenesis-related growth factors in plasma and
      efficacy, and biomarkers relevant as prognostic factors or predictive factors for
      sensitivity or resistance to treatment will be examined exploratively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS)</measure>
    <time_frame>Baseline, Cycle 8, Progression Disease</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the values of angiogenesis-related growth factors in plasma with PFS centrally assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the correlation of values of angiogenesis-related growth factors in plasma with efficacy and adverse events</measure>
    <time_frame>Baseline, Cycle 8, Progression Disease</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rate, Tumor shrinkage rate, Liver resection rate, R0 liver resection rate( pathologically confirmed ), Progression-free survival(CT/MRI image assessed by the attending physician), Time to treatment-failure, Overall survival, Incidence of adverse events (drag-related, surgery-related) , Pathological diagnosis; the patients who undergo liver resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma</measure>
    <time_frame>Baseline, Cycle 8, Progression Disease</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Only Metastasis From Colorectal Cancer ( KRAS Wild-type )</condition>
  <arm_group>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOX plus bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFOX plus cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-OHP</intervention_name>
    <description>85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>l-LV</intervention_name>
    <description>200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Levofolinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who registered the ATOM trial and signed informed consent prior to
             initiation of any trial-specific procedure and treatment.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ichinosuke Hyodo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Graduate School of Comprehensive Human Sciences, Tsukuba University, Department of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshihiro Kakeji, MD, PhD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kobe University Graduate School of Medicine, Division of Gastrointestinal Surgery, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EPS Corporation</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>112-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasumi Shimizu</last_name>
      <phone>+81-3-5684-7767</phone>
      <email>prj-atomdc@eps.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>April 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
